Anzeige
Meldung des Tages: +52% am Freitag und das könnte erst der Anfang sein: Zefiro sichert sich millionenschwere Staatsaufträge

Regenxbio News

Aktie
WKN:  A140E0 ISIN:  US75901B1070 US-Symbol:  RGNX Branche:  Biotechnologie Land:  USA
8,108 €
+0,02 €
+0,25%
10:13:39 Uhr
Depot/Watchlist
Marktkapitalisierung *
602,52 Mio. €
Streubesitz
8,44%
KGV
-1,73
Index-Zuordnung
-

Regenxbio News

29.09.25 - PR Newswire
REGENXBIO Announces Presentation at the World Muscle Society
REGENXBIO Announces Presentation at the World Muscle Society PR Newswire
05.09.25 - PR Newswire
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
REGENXBIO Presents Positive Twelve-​Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II PR Newswire
28.08.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
18.08.25 - PR Newswire
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II PR Newswire
07.08.25 - PR Newswire
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights PR Newswire
07.08.25 - PR Newswire
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy PR Newswire
31.07.25 - PR Newswire
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights PR Newswire
10.07.25 - PR Newswire
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for ...
05.06.25 - PR Newswire
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 PR Newswire
02.06.25 - PR Newswire
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 PR Newswire
19.05.25 - PR Newswire
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million PR Newswire
14.05.25 - PR Newswire
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment PR Newswire
13.05.25 - PR Newswire
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II PR Newswire
12.05.25 - PR Newswire
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights PR Newswire
08.05.25 - PR Newswire
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting PR Newswire
06.05.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
30.04.25 - PR Newswire
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr -3,12%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »